Piper Sandler reiterates Natera stock rating on CEO transition
Piper Sandler maintained an Overweight rating and $363.50 price target for Natera (NTRA) after the company announced a CEO transition and a $6B revenue target for 2029. NTRA's stock has gained 83% over the past year but declined 12% this week. Piper Sandler sees potential buying opportunities despite short-term pressure. Natera reported Q3 2026 revenue of $794M, up 34% YoY, and raised its full-year revenue forecast to $3.005B-$3.035B.
How this was made
The 30-second read
Why it matters
Analyst maintains an Overweight stance, suggesting the market may price in the leadership change gradually.
Market read
The CEO transition is the primary catalyst; the rating reiteration adds modest trading relevance.
What to watch
Potential integration challenges and capital requirements for the $6 billion revenue goal are not detailed.
Background
Piper Sandler's reiteration follows Natera's recent strong Q3 earnings and a revised full‑year revenue outlook.
Ticker impact
Piper Sandler reiterated an Overweight rating and $363.50 price target for Natera following the announcement of its new CEO, Solomon Moshkevich.
possible near‑term pressure as the market prices in the leadership change, with upside potential if growth initiatives succeed
Analyst cites a succession plan and growth roadmap; the stock is slightly overvalued but the new CEO is expected to drive revenue expansion.
Market effects
The announcement may affect other genetics and diagnostics firms as investors reassess leadership risk.
Primarily U.S. biotech sector; limited broader market effect.
Low; relevance confined to Natera and its peers.
Counterpoint
The new CEO could struggle to meet aggressive revenue targets, leading to a prolonged sell‑off.
Key entities
- companyNatera
Genomics diagnostics firm (NASDAQ:NTRA).
- research_firmPiper Sandler
Equity research firm providing the rating and price target.
